Medline ® Abstract for Reference 75
of 'Genetic counseling and testing for hereditary breast and ovarian cancer'
Declining second primary ovarian cancer after first primary breast cancer.
Schonfeld SJ, Berrington de Gonzalez A, Visvanathan K, Pfeiffer RM, Anderson WF
J Clin Oncol. 2013 Feb;31(6):738-43. Epub 2013 Jan 2.
PURPOSE: Although ovarian cancer incidence rates have declined in the United States, less is known of ovarian cancer trends among survivors of breast cancer. Therefore, we examined second primary ovarian cancers after first primary breast cancer.
METHODS: Data were obtained from the Surveillance, Epidemiology, and End Results program (1973 to 2008). Standardized incidence ratios (SIRs) were calculated as the observed numbers of ovarian cancers among survivors of breast cancer compared with the expected numbers in the general population. Absolute rates were measured as the incidence rates for second primary ovarian cancer by year of diagnosis of the first primary breast cancer adjusted for age of breast cancer diagnosis and years since diagnosis.
RESULTS: SIRs for second primary ovarian cancer were elevated over the entire study period (SIR, 1.24; 95% CI, 1.2 to 1.3), whereas the absolute rates declined with an estimated annual percentage change near 1% (-1.34% to -0.09% per year). Secular trends for second ovarian cancers were similar after estrogen receptor (ER) -positive andER-negative breast cancers, whereas the age-specific patterns varied significantly by ER expression (P for interaction<.001). The largest SIR was among women age less than 50 years with ER-negative breast cancer (SIR, 4.35; 95% CI, 3.5 to 5.4).
CONCLUSION: Persistently elevated SIRs along with decreasing absolute rates over the entire study period suggest that ovarian cancers in both the general population and survivors of breast cancer are declining in parallel, possibly because of common risk factor exposures. Analytic studies are needed to further assess the parallel overall trends and the age-specific interaction by ER expression.
Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bethesda, MD, USA.